-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shortage drugs are usually defined as clinically necessary drugs that cannot be supplied normally within a certain period of time, including drugs with uncertain dosage, low price, infrequent production by enterprises and frequent shortages in the region
.
It is understood that there are currently 409 types of medicines in short supply in China, most of which are common medicines with lower profits, rare disease medicines with low sales, and medicines that affect the blood, hematopoiesis and nervous system
.
For patients, the shortage of medicines is a major issue, which will cause anxiety and pressure for patients.
The problem of shortages of medicines has always been a concern of patients.
Due to the complex causes of shortages of medicines, which involve multiple factors such as policies and markets, once they appear, they need to be dealt with by many parties.
Cracked
.
For example, since 2021, Parkinson’s stock drug Xining (carzodopa sustained-release tablets) has risen from about 50 yuan/box to nearly 1,000 yuan/box, and there has been a shortage of supplies across the country.
One issue has attracted the attention of many parties, and the Ministry of Industry and Information Technology has also launched an investigation on it
.
In order to solve the problem of drug shortage, relevant departments of our country have also continued to make efforts in recent years
.
In April 2020, the National Health Commission and 11 member units issued the "Notice on Printing and Distributing the National Shortage Drug List Management Measures (Trial)", which clarified that the country will strengthen the shortage drug list and the key monitoring list of clinically necessary and easy-to-shortage drugs.
Monitoring and early warning of price abnormalities, strengthening price normalization supervision, intensifying the enforcement of illegal activities such as monopoly of raw materials, and properly handling the problem of excessively rapid drug price increases
.
Since 2021, the leading department of the consultation and linkage mechanism for the supply and guarantee of shortage of medicines at the national and provincial levels has worked with relevant units to focus on the implementation of the national shortage of medicines list and the key monitoring list of clinically necessary and easy-to-shortage medicines, and continue to promote the sharing of medicine-related information.
, Fully mobilize resources from all parties, and continuously improve the ability and level of supply guarantee for shortage of medicines
.
At present, all localities are taking active actions to strengthen the safeguard measures for listed drugs
.
For example, in July 2021, the Guizhou Provincial Health Commission and other 14 departments issued a notice on the issuance of the "Guizhou Province Shortage Drug List Management Measures (Trial)", clearly strengthening the list of shortage drugs and the drugs in the key monitoring list of clinically necessary and easy-to-shortage drugs Monitoring and early warning of price abnormalities, strengthening price normalization management, intensifying law enforcement on raw material drug monopoly and other behaviors, and properly handling the problem of excessively rapid drug price increases
.
In the course of work, if information on risks that may cause drug shortages is discovered, it is necessary to notify the lead unit of the provincial linkage mechanism in a timely manner
.
For related issues that cannot be dealt with at the provincial level, they shall be reported to the relevant state departments in accordance with their responsibilities
.
It is reported that the "Notice on the Management Measures for the List of Shortage Drugs in Sichuan Province (for Trial Implementation)" issued by the Sichuan Medical Insurance Bureau and other 7 departments recently also requires the development of a list of shortages in the province and a key monitoring list of clinically necessary and easy-to-shortage drugs
.
The “Notice” clarified that in accordance with the principle of “encouraging the supply of shortage drugs, preventing malicious price increases of shortage drugs and “hitching price increases” of non-shortage drugs”, the provincial-level centralized drug procurement system will be further improved to ensure that drugs are safe, effective, and reasonably priced.
Stable supply
.
The "Notice" also requires that if the drug marketing license holders in the whole province stop production, they should report to the Sichuan Provincial Drug Administration 6 months before the stop of production; if there is an unexpected stop of production, report within 3 days
.
Carry out emergency medical reserves, especially for emergency (rescue) drugs with uncertain dosages, and therapeutic drugs required for the disposal of major diseases and public health incidents.
All localities should give priority to the scope of local emergency medical supplies
.
.
It is understood that there are currently 409 types of medicines in short supply in China, most of which are common medicines with lower profits, rare disease medicines with low sales, and medicines that affect the blood, hematopoiesis and nervous system
.
For patients, the shortage of medicines is a major issue, which will cause anxiety and pressure for patients.
The problem of shortages of medicines has always been a concern of patients.
Due to the complex causes of shortages of medicines, which involve multiple factors such as policies and markets, once they appear, they need to be dealt with by many parties.
Cracked
.
For example, since 2021, Parkinson’s stock drug Xining (carzodopa sustained-release tablets) has risen from about 50 yuan/box to nearly 1,000 yuan/box, and there has been a shortage of supplies across the country.
One issue has attracted the attention of many parties, and the Ministry of Industry and Information Technology has also launched an investigation on it
.
In order to solve the problem of drug shortage, relevant departments of our country have also continued to make efforts in recent years
.
In April 2020, the National Health Commission and 11 member units issued the "Notice on Printing and Distributing the National Shortage Drug List Management Measures (Trial)", which clarified that the country will strengthen the shortage drug list and the key monitoring list of clinically necessary and easy-to-shortage drugs.
Monitoring and early warning of price abnormalities, strengthening price normalization supervision, intensifying the enforcement of illegal activities such as monopoly of raw materials, and properly handling the problem of excessively rapid drug price increases
.
Since 2021, the leading department of the consultation and linkage mechanism for the supply and guarantee of shortage of medicines at the national and provincial levels has worked with relevant units to focus on the implementation of the national shortage of medicines list and the key monitoring list of clinically necessary and easy-to-shortage medicines, and continue to promote the sharing of medicine-related information.
, Fully mobilize resources from all parties, and continuously improve the ability and level of supply guarantee for shortage of medicines
.
At present, all localities are taking active actions to strengthen the safeguard measures for listed drugs
.
For example, in July 2021, the Guizhou Provincial Health Commission and other 14 departments issued a notice on the issuance of the "Guizhou Province Shortage Drug List Management Measures (Trial)", clearly strengthening the list of shortage drugs and the drugs in the key monitoring list of clinically necessary and easy-to-shortage drugs Monitoring and early warning of price abnormalities, strengthening price normalization management, intensifying law enforcement on raw material drug monopoly and other behaviors, and properly handling the problem of excessively rapid drug price increases
.
In the course of work, if information on risks that may cause drug shortages is discovered, it is necessary to notify the lead unit of the provincial linkage mechanism in a timely manner
.
For related issues that cannot be dealt with at the provincial level, they shall be reported to the relevant state departments in accordance with their responsibilities
.
It is reported that the "Notice on the Management Measures for the List of Shortage Drugs in Sichuan Province (for Trial Implementation)" issued by the Sichuan Medical Insurance Bureau and other 7 departments recently also requires the development of a list of shortages in the province and a key monitoring list of clinically necessary and easy-to-shortage drugs
.
The “Notice” clarified that in accordance with the principle of “encouraging the supply of shortage drugs, preventing malicious price increases of shortage drugs and “hitching price increases” of non-shortage drugs”, the provincial-level centralized drug procurement system will be further improved to ensure that drugs are safe, effective, and reasonably priced.
Stable supply
.
The "Notice" also requires that if the drug marketing license holders in the whole province stop production, they should report to the Sichuan Provincial Drug Administration 6 months before the stop of production; if there is an unexpected stop of production, report within 3 days
.
Carry out emergency medical reserves, especially for emergency (rescue) drugs with uncertain dosages, and therapeutic drugs required for the disposal of major diseases and public health incidents.
All localities should give priority to the scope of local emergency medical supplies
.
